Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug screening, covalent drug discovery, mechanism of action (MOA) discovery, and target identification. By using chemical proteomics, researchers can more precisely identify interactions between small molecules and cellular targets, aiding in the development of new therapeutic candidates.
In this GEN webinar, our expert speakers will explore cutting-edge drug discovery techniques for target deconvolution and multiplex target discovery. They will also delve into how multiplex target discovery and target tractability assessment accelerate the drug discovery process. Attendees will learn how to apply target discovery and target deconvolution technologies in the early stages of drug development, enabling faster, more accurate identification of viable drug targets. Additionally, the experts will discuss the use and value of DNA-encoded libraries for target tractability assessment. Attendees will learn about the technical strengths and service opportunities available through WuXi Apptec. Key takeaways from the webinar include:
- Accelerating drug discovery and MOA studies through proteomics and target deconvolution.
- Applying multiplex target discovery and deconvolution techniques to identify promising drug targets.
- Leveraging DNA-encoded libraries for efficient target tractability assessment.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
